Literature DB >> 33735558

Prediction of Cancer Incidence and Mortality in Korea, 2021.

Kyu-Won Jung1,2, Young-Joo Won1,2,3, Seri Hong1,2, Hyun-Joo Kong1,2, Jeong-Soo Im4, Hong Gwan Seo1,3.   

Abstract

PURPOSE: This study aimed to report the projected cancer incidence and mortality for the year 2021 to estimate Korea's current cancer burden.
MATERIALS AND METHODS: Cancer incidence data from 1999 to 2018 were obtained from the Korea National Cancer Incidence Database, and cancer mortality data from 1993 to 2019 were acquired from Statistics Korea. Cancer incidence and mortality were projected by fitting a linear regression model to observed age-specific cancer rates against their respective years and then by multiplying the projected age-specific rates by the anticipated age-specific population for 2021. A joinpoint regression model was used to determine the year in which the linear trend changed significantly; we only used the data of the latest trend.
RESULTS: In total, 259,999 new cancer cases and 81,567 cancer deaths are expected to occur in Korea in 2021. The most common cancer site is expected to be the lung, followed by the thyroid, colon and rectum, breast, and stomach. These five cancers are expected to represent half of the overall burden of cancer in Korea. The most common type of cancer leading to death is expected to be lung cancer, followed by liver, colorectal, pancreatic, and stomach cancers.
CONCLUSION: The incidence rates for all types of cancer in Korea are estimated to gradually decrease. These up-to-date estimates of the cancer burden in Korea could be an important resource for planning and evaluating cancer-control programs.

Entities:  

Keywords:  2021; Forecasting; Incidence; Korea; Mortality; Neoplasms

Mesh:

Year:  2021        PMID: 33735558      PMCID: PMC8053854          DOI: 10.4143/crt.2021.290

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN: 1598-2998            Impact factor:   4.679


Introduction

As the leading cause of death in Korea [1], cancer has been a major public health concern in the country since 1983. More than 230,000 patients were newly diagnosed with cancer in Korea, and one-fourth of deaths were due to cancer in 2017 [2]. Although the cancer registration system in Korea is highly efficient and can provide nationwide cancer statistics within a relatively short period, a lag time of at least 2 years is required to collect and analyze data for a specific year. For planning and implementing comprehensive cancer-control programs, it is important to assess the number of new cases and deaths that are expected to occur during the current year. In this study, we report the projected cancer incidence and mortality for the year 2021 based on data from the 1990s to 2018.

Materials and Methods

The Korean Ministry of Health and Welfare initiated a nationwide, hospital-based cancer registry, known as the Korea Central Cancer Registry (KCCR), in 1980. The history, objectives, and activities of the KCCR have been documented in detail elsewhere [3]. Cancer incidence data from 1999 to 2018 were obtained from the Korea National Cancer Incidence Database (KNCI DB). Cancer cases were classified according to the International Classification of Diseases for Oncology, 3rd edition [4] and converted according to the International Classification of Diseases, 10th edition (ICD-10) [5]. Mortality data from 1993 to 2019 were acquired from Statistics Korea [1]. The cause of death was coded and classified according to the ICD-10 [5]. The cancer sites included in this study were (1) all cancer sites combined and (2) the 24 cancer sites as follows: lips, oral cavity, and pharynx (C00-C14), esophagus (C15), stomach (C16), colon and rectum (C18-C20), liver (C22), gallbladder etc. (C23-C24), pancreas (C25), larynx (C32), lung (C33-C34), breast (C50), cervix uteri (C53), corpus uteri (C54), ovary (C56), prostate (C61), testis (C62), kidney (C64), bladder (C67), brain and central nervous system (C70-C72), thyroid (C73), Hodgkin lymphoma (C81), non-Hodgkin lymphoma (C82-C86, C96), multiple myeloma (C90), leukemia (C91-C95), and other and ill-defined sites (remainder of C00-C96). The population data were obtained from the resident registration population data, reported by Statistics Korea. Data of the mid-year population (July 1 of the respective year) were used as the denominator to obtain the annual incidence and mortality rates. However, for the year 2021, we used the population data on December 31, 2020, as the mid-2021 resident registration population data were not yet available at the time of the analysis. Linear regression models [6] were used to assess time trends and create projections. We first performed a joinpoint regression analysis on the data available to detect the year when significant changes occurred in cancer trends according to sex and cancer site. A joinpoint regression describes changes in data trends by connecting several different line segments on a log scale at “joinpoints.” This analysis was performed using Joinpoint software (version 4.7.0.0; http://surveillance.cancer.gov/joinpoint) from the Surveillance Research Program of the US National Cancer Institute [7]. For the analysis, we arranged to have at least four data points between consecutive joinpoints. Secondly, to predict age-specific cancer rates, a linear regression model was fitted to age-specific rates by 5-year age groups against their respective years, based on the observed cancer incidence data of the latest trends. Finally, we multiplied the projected age-specific rates by the age-specific population to get the projected number of cancer cases and deaths for the year 2021. We summarized the results using crude rates (CRs) and age-standardized rates (ASRs) of cancer incidence and mortality. ASRs were standardized using the world standard population [8] and expressed per 100,000 persons.

Results

1. Incidence

In total, 259,999 new cancer cases are expected to occur in 2021 (Table 1, Fig. 1); more men (n=135,577) than women (n=124,422) are expected to be affected.
Table 1

Estimated new cancer cases and deaths by sex during 2021 in Korea

SiteEstimated new casesEstimated deaths


Both sexesMenWomenBoth sexesMenWomen
All sites259,999135,577124,42281,56749,63031,937

Lip, oral cavity, and pharynx4,0772,9261,1511,257913344

Esophagus2,6222,3792431,2601,125135

Stomach26,76817,8998,8695,8083,8421,966

Colon and rectum28,17717,11011,0678,8654,9073,958

Liver[a)]14,70710,9913,7169,8567,0332,823

Gallbladder[b)]8,3384,4603,8785,3872,8902,497

Pancreas8,8124,5694,2437,0313,6343,397

Larynx1,0661,0056125023119

Lung[c)]32,14921,20610,94318,37913,6114,768

Breast26,92610226,8242,840182,822

Cervix uteri3,105-3,105794-794

Corpus uteri3,467-3,467403-403

Ovary3,080-3,0801,344-1,344

Prostate16,74916,749-2,1402,140-

Testis326326-1818-

Kidney6,2444,2901,9541,174814360

Bladder5,0674,0201,0471,5641,157407

Brain and CNS2,1701,1651,0051,387719668

Thyroid31,1447,93823,20634498246

Hodgkin lymphoma350216134643925

Non-Hodgkin lymphoma5,7913,3332,4582,2471,288959

Multiple myeloma2,0121,0469661,171639532

Leukemia3,8652,2371,6282,1021,231871

Other and ill defined22,98711,61011,3775,8823,2832,599

CNS, central nervous system.

Includes the liver and intrahepatic bile duct,

Includes the gallbladder and other/unspecified parts of the biliary tract,

Includes the lung and bronchus.

Fig. 1

The 10 leading types of estimated new cancer cases and deaths by sex in 2021. (A) Estimated new cases. (B) Estimated deaths.

The projected CRs per 100,000 for all of the sites combined in 2021 are 524.7 cases and 478.8 cases for men and women, respectively (Table 2). The projected ASRs per 100,000 for all of the sites combined are 280.0 cases and 265.2 cases for men and women, respectively. In men, the five leading primary sites of cancer are expected to be the lung (CR, 82.1; ASR, 39.7), stomach (CR, 69.3; ASR, 35.8), colon and rectum (CR, 66.2; ASR, 34.4), prostate (CR, 64.8; ASR, 31.5), and liver (CR, 42.5; ASR, 22.0), accounting for 61.9% of all new cancer cases in 2021. In women, the five leading primary sites are expected to be the breast (CR, 103.2; ASR, 63.6), thyroid (CR, 89.3; ASR, 66.3), colon and rectum (CR, 42.6; ASR, 17.7), lung (CR, 42.1; ASR, 18.1), and stomach (CR, 34.1; ASR, 15.7), accounting for 65.0% of all new cancer cases in 2021 (Fig. 1).
Table 2

Estimated crude and age-standardized cancer incidences by sex during 2021 in Korea

SiteCrude incidence rates per 100,000Age-standardized incidence rates per 100,000[a)]


Both sexesMenWomenBoth sexesMenWomen
All sites501.7524.7478.8266.5280.0265.2

Lip, oral cavity, and pharynx7.911.34.44.36.32.5

Esophagus5.19.20.92.34.50.4

Stomach51.769.334.125.035.815.7

Colon and rectum54.466.242.625.634.417.7

Liver[b)]28.442.514.313.522.05.8

Gallbladder[c)]16.117.314.96.78.35.4

Pancreas17.017.716.37.68.96.5

Larynx2.13.90.20.91.90.1

Lung[d)]62.082.142.127.539.718.1

Breast52.00.4103.231.90.263.6

Cervix uteri6.0-12.03.9-7.8

Corpus uteri6.7-13.34.0-8.0

Ovary5.9-11.93.6-7.2

Prostate32.364.8-14.331.5-

Testis0.61.3-0.71.3-

Kidney12.116.67.56.79.63.9

Bladder9.815.64.04.27.61.6

Brain and CNS4.24.53.93.03.42.7

Thyroid60.130.789.343.822.166.3

Hodgkin lymphoma0.70.80.50.60.70.5

Non-Hodgkin lymphoma11.212.99.56.68.15.3

Multiple myeloma3.94.13.71.82.01.6

Leukemia7.58.76.35.66.64.6

Other and ill defined44.444.943.822.725.420.3

CNS, central nervous system.

Age adjusted to the world standard population,

Includes the liver and intrahepatic bile duct,

Includes the gallbladder and other/unspecified parts of the biliary tract,

Includes the lung and bronchus.

The five most common cancer sites expected in 2021 according to sex and age group are shown in Table 3. Leukemia and thyroid cancer are expected to be the most common forms of cancer in both sexes for those aged 0–14 years and 15–34 years, respectively. Stomach cancer is predicted to be the most prevalent cancer in men aged 35–64 years, while lung cancer is expected to be more frequent in men aged 65 years and above. Breast cancer is predicted to be the most common cancer in women aged 35–64 years, whereas colorectal cancer is expected to be the most common form in women aged 65 years and above. According to the projection, the incidences of stomach, lung, liver, colorectal, and prostate cancers will increase gradually with age for men (Fig. 2A). In women, the age-specific incidence rates for stomach, colorectal, liver, lung, and cervical cancers denote an increasing trend with age; however, the incidences of breast and thyroid cancers in women are expected to level off after the age of 45 and 50 years, respectively (Fig. 2B).
Table 3

Estimated cancer incidence by age group and sex during 2021 in Korea

RankAge group (yr)
0–1415–3435–64≥65
Men
 1Leukemia (4.8)Thyroid (22.9)Stomach (65.3)Lung[a)] (426.0)
 2Non-Hodgkin lymphoma (3.3)Leukemia (3.9)Colon and rectum (61.7)Prostate (351.5)
 3Brain and CNS (2.3)Non-Hodgkin lymphoma (3.3)Thyroid (44.4)Stomach (264.8)
 4Kidney (0.4)Testis (3.0)Lung[a)] (44.0)Colon and rectum (251.3)
 5Testis (0.3)Colon and rectum (2.9)Liverb) (42.3)Liver[b)] (154.5)
Women
 1Leukemia (4.0)Thyroid (69.3)Breast (171.6)Colon and rectum (150.0)
 2Brain and CNS (2.1)Breast (12.1)Thyroid (135.1)Lung[a)] (142.8)
 3Non-Hodgkin lymphoma (1.7)Cervix uteri (5.6)Lung[a)] (33.0)Breast (108.0)
 4Ovary (0.8)Ovary (3.5)Stomach (30.9)Stomach (104.3)
 5Thyroid (0.6)Corpus uteri (2.7)Colon and rectum (30.5)Pancreas (65.1)

CNS, central nervous system.

Includes the lung and bronchus,

Includes the liver and intrahepatic bile duct.

Fig. 2

Projected age-specific incidences of major cancers during 2021 in Korea. (A) Men. (B) Women.

2. Mortality

It is estimated that 81,567 cancer deaths will occur in Korea during 2021 (Table 1, Fig. 1). The projected CRs per 100,000 for all of the sites combined in 2021 for men and women are 192.1 cases and 122.9 cases, respectively, whereas the projected ASRs per 100,000 for all sites combined for men and women are expected to be 92.6 cases and 45.5 cases, respectively (Table 4). The predicted five leading cancer sites causing mortality in men are the lung (CR, 52.7; ASR, 24.4), liver (CR, 27.2; ASR, 13.5), colon and rectum (CR, 19.0; ASR, 9.2), stomach (CR, 14.9; ASR, 7.2), and pancreas (CR, 14.1; ASR, 6.9). During the same period, lung cancer (CR, 18.4; ASR, 6.2) is projected to be the leading cause of cancer death in women, followed by colon and rectal (CR, 15.2; ASR, 4.9), pancreatic (CR, 13.1; ASR, 4.6), liver (CR, 10.9; ASR, 3.6), and breast (CR, 10.9; ASR, 5.7) cancers.
Table 4

Estimated crude and age-standardized cancer mortality rates by sex during 2021 in Korea

SiteCrude mortality rates per 100,000Age-standardized mortality rates per 100,000[a)]


Both sexesMenWomenBoth sexesMenWomen
All sites157.4192.1122.965.692.645.5

Lip, oral cavity, and pharynx2.43.51.31.11.80.5

Esophagus2.44.40.51.02.00.2

Stomach11.214.97.64.57.22.4

Colon and rectum17.119.015.26.89.24.9

Liver[b)]19.027.210.98.313.53.6

Gallbladder[c)]10.411.29.64.05.22.9

Pancreas13.614.113.15.66.94.6

Larynx0.50.90.10.20.40.0

Lung[d)]35.552.718.414.024.46.2

Breast5.50.110.92.90.05.7

Cervix uteri1.5-3.10.8-1.5

Corpus uteri0.8-1.60.4-0.7

Ovary2.6-5.21.3-2.4

Prostate4.18.3-1.43.7-

Testis0.00.1-0.00.1-

Kidney2.33.21.41.01.60.5

Bladder3.04.51.61.12.10.4

Brain and CNS2.72.82.61.61.71.4

Thyroid0.70.41.00.20.20.3

Hodgkin lymphoma0.10.20.10.10.10.0

Non-Hodgkin lymphoma4.35.03.71.82.41.3

Multiple myeloma2.32.52.10.91.20.7

Leukemia4.14.83.42.02.61.5

Other and ill defined11.412.710.04.96.53.7

CNS, central nervous system.

Age adjusted to the world standard population,

Includes the liver and intrahepatic bile duct,

Includes the gallbladder and other/unspecified parts of the biliary tract,

Includes the lung and bronchus.

The predicted age-specific mortality rates of the leading causes of cancer-associated death in men and women in 2021 are shown in detail in Fig. 3. According to age, Korean men and women aged at least 60 years are expected to have the highest mortality rates due to lung cancer.
Fig. 3

Projected age-specific mortality rates of major cancers during 2021 in Korea. (A) Men. (B). Women.

Conclusion

A total of 259,999 new cancer cases and 81,567 cancer deaths are expected to occur in Korea during 2021. Lung cancer is predicted to be the most common type of cancer among men, followed by stomach, colorectal, prostate, and liver cancers. Lung, liver, colorectal, stomach, and pancreatic cancers are expected to be the most common causes of cancer deaths among men. In women, the five leading primary cancer sites are expected to be the breast, thyroid, colon and rectum, lung, and stomach, while lung, colorectal, pancreatic, liver, and breast cancers are projected to be the most common causes of cancer deaths. Cancer is currently one of the foremost public health concerns in Korea. Although cancer incidence rates are anticipated to slightly decrease, the burden of most types of cancers will continue to grow with the increasing age of the population. The current projections of cancer incidence and mortality for 2021 represent an important resource for planning and evaluating cancer-control programs. As the estimates in this study are model-based, these results should be interpreted with caution.
  3 in total

Review 1.  Cancer registration: principles and methods. Statistical methods for registries.

Authors:  P Boyle; D M Parkin
Journal:  IARC Sci Publ       Date:  1991

2.  Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database.

Authors:  Hai-Rim Shin; Young-Joo Won; Kyu-Won Jung; Hyun-Joo Kong; Seon-Hee Yim; Jung-Kyu Lee; Hong-In Noh; Jong-Koo Lee; Paola Pisani; Jae-Gahb Park
Journal:  Cancer Res Treat       Date:  2005-12-31       Impact factor: 4.679

3.  Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2017.

Authors:  Seri Hong; Young-Joo Won; Young Ran Park; Kyu-Won Jung; Hyun-Joo Kong; Eun Sook Lee
Journal:  Cancer Res Treat       Date:  2020-03-16       Impact factor: 4.679

  3 in total
  19 in total

1.  Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase.

Authors:  Hye-Young Min; Ho Jin Lee; Young-Ah Suh; Honglan Pei; Hyukjin Kwon; Hyun-Ji Jang; Hye Jeong Yun; Hyeong-Gon Moon; Ho-Young Lee
Journal:  Br J Cancer       Date:  2022-05-21       Impact factor: 9.075

2.  Seaweed and Iodine Intakes and SLC5A5 rs77277498 in Relation to Thyroid Cancer.

Authors:  Tung Hoang; Eun Kyung Lee; Jeonghee Lee; Yul Hwangbo; Jeongseon Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2022-05-24

3.  Trend Analysis and Prediction of Hepatobiliary Pancreatic Cancer Incidence and Mortality in Korea.

Authors:  Hyeong Min Park; Young-Joo Won; Mee Joo Kang; Sang-Jae Park; Sun-Whe Kim; Kyu-Won Jung; Sung-Sik Han
Journal:  J Korean Med Sci       Date:  2022-07-18       Impact factor: 5.354

4.  Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01).

Authors:  Ji Hyun Kim; Dong-Eun Lee; Yumi Lee; Hyeong In Ha; Yoon Jung Chang; Suk-Joon Chang; Sang-Yoon Park; Myong Cheol Lim
Journal:  J Gynecol Oncol       Date:  2022-05-31       Impact factor: 4.756

5.  Colonoscopy Insertion in Patients with Gastrectomy: Does Position Impact Cecal Intubation Time?

Authors:  Jae Hyun Kim; Youn Jung Choi; Hye Jung Kwon; Gyu Man Oh; Kyoungwon Jung; Sung Eun Kim; Won Moon; Moo In Park; Seun Ja Park
Journal:  Dig Dis Sci       Date:  2022-02-05       Impact factor: 3.487

6.  Current Status of Lung Cancer and Surgery Based on Studies Using a Nationwide Database.

Authors:  Dohun Kim; Jung-Won Lee
Journal:  J Chest Surg       Date:  2022-02-05

7.  Preoperative neutrophil-to-lymphocyte, platelet-to-lymphocyte and monocyte-to-lymphocyte ratio as a prognostic factor in non-endometrioid endometrial cancer.

Authors:  Heekyoung Song; Min Jin Jeong; Jimin Cha; Ji Sun Lee; Ji Geun Yoo; Min Jong Song; Jin Hwi Kim; Sung Jong Lee; Hae Nam Lee; Joo Hee Yoon; Dong Choon Park; Sang Il Kim
Journal:  Int J Med Sci       Date:  2021-09-24       Impact factor: 3.738

8.  Ninjurin1 drives lung tumor formation and progression by potentiating Wnt/β-Catenin signaling through Frizzled2-LRP6 assembly.

Authors:  Seung Yeob Hyun; Hye-Young Min; Ho Jin Lee; Jaebeom Cho; Hye-Jin Boo; Myungkyung Noh; Hyun-Ji Jang; Hyo-Jong Lee; Choon-Sik Park; Jong-Sook Park; Young Kee Shin; Ho-Young Lee
Journal:  J Exp Clin Cancer Res       Date:  2022-04-08

9.  Association between Statin Use and Gastric Cancer: A Nested Case-Control Study Using a National Health Screening Cohort in Korea.

Authors:  Mi Jung Kwon; Ho Suk Kang; Joo-Hee Kim; Ji Hee Kim; Se Hoon Kim; Nan Young Kim; Eun Sook Nam; Kyueng-Whan Min; Hyo Geun Choi
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-08

10.  The Current Status of Integrative Oncology in Korea.

Authors:  Eun-Bin Kwag; Soo-Dam Kim; Ji Hye Park; So-Jung Park; Mi-Kyung Jeong; Hwa-Seung Yoo
Journal:  Integr Cancer Ther       Date:  2021 Jan-Dec       Impact factor: 3.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.